GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Equity-to-Asset

Argenica Therapeutics (ASX:AGN) Equity-to-Asset : 0.77 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Argenica Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$6.59 Mil. Argenica Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was A$8.62 Mil.

The historical rank and industry rank for Argenica Therapeutics's Equity-to-Asset or its related term are showing as below:

ASX:AGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.77   Med: 0.92   Max: 0.99
Current: 0.77

During the past 3 years, the highest Equity to Asset Ratio of Argenica Therapeutics was 0.99. The lowest was 0.77. And the median was 0.92.

ASX:AGN's Equity-to-Asset is ranked better than
62.67% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs ASX:AGN: 0.77

Argenica Therapeutics Equity-to-Asset Historical Data

The historical data trend for Argenica Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Equity-to-Asset Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Equity-to-Asset
0.94 0.92 0.80

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial 0.99 0.92 0.84 0.80 0.77

Competitive Comparison of Argenica Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Argenica Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argenica Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argenica Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Argenica Therapeutics's Equity-to-Asset falls into.



Argenica Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Argenica Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=7.666/9.541
=

Argenica Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=6.594/8.621
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Argenica Therapeutics  (ASX:AGN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Argenica Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Argenica Therapeutics (ASX:AGN) Business Description

Traded in Other Exchanges
N/A
Address
117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines